| Sie befinden sich in - ||Home|| - ||Fulvestrant (L02BA03)|
|L02BA03 - Fulvestrant||ATC-DDD Version 2016. Source: WHO|
|L - Antineoplastic and Immunomodulating Agents|
This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|L02 - Endocrine Therapy|
Estrogens and progestogens used specifically in the treatment of neoplastic diseases are classified in this group. This means that some strengths may be classified in this group, while remaining strengths are classified in G03 - Sex hormones and modulators of the genital system.
The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).
|L02B - Hormone Antagonists and Related Agents|
|L02BA03 - Fulvestrant|
|8.3 mg||P|| |